Capricor Therapeutics (CAPR) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts CAPR Hot Sheet
Join SI Premium – FREE
Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $10.6 million.
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare on Medicare rating changes
- Novagold Resources, Inc. (NG) Misses Q3 EPS by 2c
- Lamb Weston (LW) Tops Q1 EPS by 15c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
